Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 inhibitor plus chemotherapy for 2 versus 3 cycles before surgery in locally advanced esophageal squamous cell carcinoma
ChiCTR2300072755Phase 3Not yet recruiting
- Sponsor
- Jining First People's Hospital
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Jining First People's Hospital. Primary endpoints: Objective response rate, Pathological response rate and 3 more. Planned start Jun 2023; status: not yet recruiting.
02
Drugs
cisplatinpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2300072755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300072755.